Search

Your search keyword '"Vastert, Sebastiaan J."' showing total 473 results
Start Over Author "Vastert, Sebastiaan J."
473 results on '"Vastert, Sebastiaan J."'

151. Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: A study protocol

Author

Immuno/reuma onderzoek 1 (Vastert), Immuno/reuma patientenzorg, Child Health, Immuno/reuma onderzoek 5 (Vastert2), Infection & Immunity, Immuno/reuma onderzoek 3 (Loosdregt), Onderzoek, Reumatologie patientenzorg, MS Oogheelkunde, Cluster Ontwikkelingsgerichte zorg, Kinderbewegingszorg patientenzorg, Medical Humanities Onderzoek Team 2, JC onderzoeksprogramma Methodology, Cluster B, Regenerative Medicine and Stem Cells, Immunologie/Reumatologie, Schoemaker, Casper G., Armbrust, Wineke, Swart, Joost F., Vastert, Sebastiaan J., Van Loosdregt, Jorg, Verwoerd, Anouk, Whiting, Caroline, Cowan, Katherine, Olsder, Wendy, Versluis, Els, Van Vliet, Rens, Fernhout, Marlous J., Bookelman, Sanne L., Cappon, Jeannette, Van Den Berg, J. Merlijn, Schatorjé, Ellen, Muller, Petra C.E.Hissink, Kamphuis, Sylvia, De Boer, Joke, Lelieveld, Otto T.H.M., Van Der Net, Janjaap, Jongsma, Karin R., Van Rensen, Annemiek, Dedding, Christine, Wulffraat, Nico M., Immuno/reuma onderzoek 1 (Vastert), Immuno/reuma patientenzorg, Child Health, Immuno/reuma onderzoek 5 (Vastert2), Infection & Immunity, Immuno/reuma onderzoek 3 (Loosdregt), Onderzoek, Reumatologie patientenzorg, MS Oogheelkunde, Cluster Ontwikkelingsgerichte zorg, Kinderbewegingszorg patientenzorg, Medical Humanities Onderzoek Team 2, JC onderzoeksprogramma Methodology, Cluster B, Regenerative Medicine and Stem Cells, Immunologie/Reumatologie, Schoemaker, Casper G., Armbrust, Wineke, Swart, Joost F., Vastert, Sebastiaan J., Van Loosdregt, Jorg, Verwoerd, Anouk, Whiting, Caroline, Cowan, Katherine, Olsder, Wendy, Versluis, Els, Van Vliet, Rens, Fernhout, Marlous J., Bookelman, Sanne L., Cappon, Jeannette, Van Den Berg, J. Merlijn, Schatorjé, Ellen, Muller, Petra C.E.Hissink, Kamphuis, Sylvia, De Boer, Joke, Lelieveld, Otto T.H.M., Van Der Net, Janjaap, Jongsma, Karin R., Van Rensen, Annemiek, Dedding, Christine, and Wulffraat, Nico M.

Published
2018

152. Prediction of inactive disease in juvenile idiopathic arthritis: A multicentre observational cohort study

Author

Immuno/reuma onderzoek 1 (Vastert), Child Health, Infection & Immunity, Immuno/reuma onderzoek 5 (Vastert2), Van Dijkhuizen, Evert H.Pieter, Aidonopoulos, Orfeas, Ter Haar, Nienke M., Pires Marafon, Denise, Magni-Manzoni, Silvia, Ioannidis, Yannis E., Putignani, Lorenza, Vastert, Sebastiaan J., Malattia, Clara, De Benedetti, Fabrizio, Martini, Alberto, Immuno/reuma onderzoek 1 (Vastert), Child Health, Infection & Immunity, Immuno/reuma onderzoek 5 (Vastert2), Van Dijkhuizen, Evert H.Pieter, Aidonopoulos, Orfeas, Ter Haar, Nienke M., Pires Marafon, Denise, Magni-Manzoni, Silvia, Ioannidis, Yannis E., Putignani, Lorenza, Vastert, Sebastiaan J., Malattia, Clara, De Benedetti, Fabrizio, and Martini, Alberto

Published
2018

155. Treating juvenile idiopathic arthritis to target: Recommendations of an international task force

Author

Cluster B, Divisieleiding O&O, Immuno/reuma onderzoek 1 (Vastert), Child Health, Regenerative Medicine and Stem Cells, Infection & Immunity, BOO, Infectiezieken, Onderzoek, Reumatologie, Immuno/reuma patientenzorg, Reumatologie patientenzorg, Immuno/reuma onderzoek 5 (Vastert2), Ravelli, Angelo, Consolaro, Alessandro, Horneff, Gerd, Laxer, Ronald M., Lovell, Daniel J., Wulffraat, Nico M., Akikusa, Jonathan D., Al-Mayouf, Sulaiman M., Antón, Jordi, Avcin, Tadej, Berard, Roberta A., Beresford, Michael W., Burgos-Vargas, Ruben, Cimaz, Rolando, De Benedetti, Fabrizio, Demirkaya, Erkan, Foell, Dirk, Itoh, Yasuhiko, Lahdenne, Pekka, Morgan, Esi M., Quartier, Pierre, Ruperto, Nicolino, Russo, Ricardo, Saad-Magalhães, Claudia, Sawhney, Sujata, Scott, Christiaan, Shenoi, Susan, Swart, Joost F., Uziel, Yosef, Vastert, Sebastiaan J., Smolen, Josef S., Cluster B, Divisieleiding O&O, Immuno/reuma onderzoek 1 (Vastert), Child Health, Regenerative Medicine and Stem Cells, Infection & Immunity, BOO, Infectiezieken, Onderzoek, Reumatologie, Immuno/reuma patientenzorg, Reumatologie patientenzorg, Immuno/reuma onderzoek 5 (Vastert2), Ravelli, Angelo, Consolaro, Alessandro, Horneff, Gerd, Laxer, Ronald M., Lovell, Daniel J., Wulffraat, Nico M., Akikusa, Jonathan D., Al-Mayouf, Sulaiman M., Antón, Jordi, Avcin, Tadej, Berard, Roberta A., Beresford, Michael W., Burgos-Vargas, Ruben, Cimaz, Rolando, De Benedetti, Fabrizio, Demirkaya, Erkan, Foell, Dirk, Itoh, Yasuhiko, Lahdenne, Pekka, Morgan, Esi M., Quartier, Pierre, Ruperto, Nicolino, Russo, Ricardo, Saad-Magalhães, Claudia, Sawhney, Sujata, Scott, Christiaan, Shenoi, Susan, Swart, Joost F., Uziel, Yosef, Vastert, Sebastiaan J., and Smolen, Josef S.

Published
2018

156. The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey

Author

Poli Van Creveldkliniek Medisch, CTI Vastert, Child Health, Infection & Immunity, Reumatologie patientenzorg, Cluster B, Divisieleiding O&O, Reumatologie, Regenerative Medicine and Stem Cells, BOO, Immunologie/Reumatologie, Infectiezieken, Immuno/reuma onderzoek 1 (Vastert), Reumatologie onderzoek 2, Arts-assistenten Kinderen, Jeyaratnam, Jerold, Ter Haar, Nienke M, Lachmann, Helen J, Kasapcopur, Ozgur, Ombrello, Amanda K, Rigante, Donato, Dedeoglu, Fatma, Baris, Ezgi H, Vastert, Sebastiaan J, Wulffraat, Nico M, Frenkel, Joost, Poli Van Creveldkliniek Medisch, CTI Vastert, Child Health, Infection & Immunity, Reumatologie patientenzorg, Cluster B, Divisieleiding O&O, Reumatologie, Regenerative Medicine and Stem Cells, BOO, Immunologie/Reumatologie, Infectiezieken, Immuno/reuma onderzoek 1 (Vastert), Reumatologie onderzoek 2, Arts-assistenten Kinderen, Jeyaratnam, Jerold, Ter Haar, Nienke M, Lachmann, Helen J, Kasapcopur, Ozgur, Ombrello, Amanda K, Rigante, Donato, Dedeoglu, Fatma, Baris, Ezgi H, Vastert, Sebastiaan J, Wulffraat, Nico M, and Frenkel, Joost

Published
2018

157. Patient's experiences with the care for juvenile idiopathic arthritis across Europe

Author

Immuno/reuma onderzoek 1 (Vastert), Reumatologie patientenzorg, Child Health, Infection & Immunity, Cluster B, Divisieleiding O&O, Regenerative Medicine and Stem Cells, BOO, Infectiezieken, Reumatologie onderzoek 2, van Dijkhuizen, E H Pieter, Egert, Tsipi, Egert, Yona, Costello, Wendy, Schoemaker, Casper, Fernhout, Marlous, Kepic, Mirjam, Martini, Alberto, Scala, Silvia, Rotstein-Grein, Ingrid, Vastert, Sebastiaan J, Wulffraat, Nico M, Immuno/reuma onderzoek 1 (Vastert), Reumatologie patientenzorg, Child Health, Infection & Immunity, Cluster B, Divisieleiding O&O, Regenerative Medicine and Stem Cells, BOO, Infectiezieken, Reumatologie onderzoek 2, van Dijkhuizen, E H Pieter, Egert, Tsipi, Egert, Yona, Costello, Wendy, Schoemaker, Casper, Fernhout, Marlous, Kepic, Mirjam, Martini, Alberto, Scala, Silvia, Rotstein-Grein, Ingrid, Vastert, Sebastiaan J, and Wulffraat, Nico M

Published
2018

158. Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method:A study protocol

Author

Schoemaker, Casper G., Armbrust, Wineke, Swart, Joost F., Vastert, Sebastiaan J., Van Loosdregt, Jorg, Verwoerd, Anouk, Whiting, Caroline, Cowan, Katherine, Olsder, Wendy, Versluis, Els, Van Vliet, Rens, Fernhout, Marlous J., Bookelman, Sanne L., Cappon, Jeannette, Van Den Berg, J. Merlijn, Schatorjé, Ellen, Muller, Petra C.E.Hissink, Kamphuis, Sylvia, De Boer, Joke, Lelieveld, Otto T.H.M., Van Der Net, Janjaap, Jongsma, Karin R., Van Rensen, Annemiek, Dedding, Christine, Wulffraat, Nico M., Schoemaker, Casper G., Armbrust, Wineke, Swart, Joost F., Vastert, Sebastiaan J., Van Loosdregt, Jorg, Verwoerd, Anouk, Whiting, Caroline, Cowan, Katherine, Olsder, Wendy, Versluis, Els, Van Vliet, Rens, Fernhout, Marlous J., Bookelman, Sanne L., Cappon, Jeannette, Van Den Berg, J. Merlijn, Schatorjé, Ellen, Muller, Petra C.E.Hissink, Kamphuis, Sylvia, De Boer, Joke, Lelieveld, Otto T.H.M., Van Der Net, Janjaap, Jongsma, Karin R., Van Rensen, Annemiek, Dedding, Christine, and Wulffraat, Nico M.

Abstract

Background: Research on Juvenile Idiopathic Arthritis (JIA) should support patients, caregivers/parents (carers) and clinicians to make important decisions in the consulting room and eventually to improve the lives of patients with JIA. Thus far these end-users of JIA-research have rarely been involved in the prioritisation of future research. Main body: Dutch organisations of patients, carers and clinicians will collaboratively develop a research agenda for JIA, following the James Lind Alliance (JLA) methodology. In a 'Priority Setting Partnership' (PSP), they will gradually establish a top 10 list of the most important unanswered research questions for JIA. In this process the input from clinicians, patients and their carers will be equally valued. Additionally, focus groups will be organised to involve young people with JIA. The involvement of all contributors will be monitored and evaluated. In this manner, the project will contribute to the growing body of literature on how to involve young people in agenda setting in a meaningful way. Conclusion: A JIA research agenda established through the JLA method and thus co-created by patients, carers and clinicians will inform researchers and research funders about the most important research questions for JIA. This will lead to research that really matters.

Published
2018

159. Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis.

Author

Wennink, Roos A. W., Ayuso, Viera Kalinina, de Vries, Lieuwe A., Vastert, Sebastiaan J., and de Boer, Joke H.

Subjects
IRIDOCYCLITIS, TOCILIZUMAB, JUVENILE diseases, UVEITIS, THERAPEUTICS
Abstract

Purpose: To describe the results of tocilizumab treatment in children with refractory non-anterior uveitis. Methods: A case series of seven children with refractory non-anterior uveitis (onset ≤16 years) with leakage on fluorescein angiogram (FA) were treated with tocilizumab intravenously every 4 weeks (eight mg/kg). Minimum follow-up was 6 months. Reported outcomes are changes in BCVA, central macular thickness (CMT) on OCT image, FA scores, dose of systemic steroids, complications and side effects. Results: In all patients, there was an improvement of macular edema and capillary leakage on FA. The median FA score decreased from 14 (10–18) at baseline to 8 (2–9) after 6 months of treatment (p =.018). The CMT decreased from 321 (314–384) to 295 (255–312) (p =.043). BCVA improved in five eyes and worsened in one eye due to cataract. No systemic or ocular complications were reported. Conclusion: Tocilizumab is an effective therapeutic option for reducing disease activity in children with refractory non-anterior uveitis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

160. Contributors

Author

Abinun, Mario, Aggarwal, Amita, Akikusa, Jonathan, Allen, Roger, Alsaeid, Khaled, Avčin, Tadej, Balevic, Stephen, Banwell, Brenda, Barron, Karyl, Barsalou, Julie, Becker, Mara L., Behrens, Edward M., Beresford, Michael W., Beukelman, Timothy, Bockenstedt, Linda K., Brogan, Paul, Brunner, Hermine I., Burns, Jane C., Busch, Robert, Cabral, David A., Canna, Scott W., Choo, Sharon, Cimaz, Rolando, Ciurtin, Coziana, Clinch, Jacqui, Colbert, Robert A., Consolaro, Alessandro, Cooper, Jennifer C., Cron, Randy Q., Davidson, Iris, Dusser, Perrine, Eleftheriou, Despina, Feldman, Brian Michael, Ferguson, Polly J., Foster, Helen Elisabeth, Fuhlbrigge, Robert C., Funk, Ryan S., Gattorno, Marco, Giancane, Gabriella, Griffiths, Anne, Grom, Alexei A., Harel, Liora, Hashkes, Philip J., Hedrich, Christian Michael, Horneff, Gerd, Houghton, Kristin Michelle, Jaeggi, Edgar, Jariwala, Mehul, Jones, Jordan T., Kastner, Daniel L., Kimura, Yukiko, Klein-Gitelman, Marisa S., Koné-Paut, Isabelle, Laxer, Ronald M., Anne LeBlanc, Claire Marie, Li, Suzanne C., Lindsley, Carol B., Martini, Alberto, Mellins, Elizabeth, Morishita, Kimberly A., Muscal, Eyal, Newburger, Jane W., Nigrovic, Peter A., Nott, Kerstin A., O’Neil, Kathleen M., Ombrello, Michael J., Orme, Lisa, Ozen, Seza, Petty, Ross E., Pilkington, Clarissa A., Pope, Elena, Prahalad, Sampath, Prescott, Steven A., Pääkkönen, Markus, Rabinovich, C. Egla, Ramanan, Athimalaipet V., Ravelli, Angelo, Ricciuto, Amanda, Ringold, Sarah, Rosenbaum, James Todd, Rosenberg, Alan M., Rosendahl, Karen, Rosser, Elizabeth C., Rosé, Carlos Daniel, Roth, Johannes, Ruperto, Nicolino, Schulert, Grant, Scott, Christiaan, Sen, Ethan S., Sherry, David D., Silverman, Earl D., Son, Mary Beth F., Sontichai, Watchareewan, Stevens, Anne M., Stinson, Jennifer N., Stoll, Matthew L., Sullivan, Kathleen, Takken, Tim, Torok, Kathryn S., Tse, Shirley M.L., Tucker, Lori, Unger, Sheila, Uziel, Yosef, van der Net, Janjaap, Vastert, Sebastiaan J., Ward, Leanne M., Wedderburn, Lucy R., Weiss, Pamela F., Wouters, Carine Helena, and Zemel, Lawrence

Published
2021
Full Text
View/download PDF

162. Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study

Author

van Dijkhuizen, Evert H Pieter, primary, Aidonopoulos, Orfeas, additional, ter Haar, Nienke M, additional, Pires Marafon, Denise, additional, Magni-Manzoni, Silvia, additional, Ioannidis, Yannis E, additional, Putignani, Lorenza, additional, Vastert, Sebastiaan J, additional, Malattia, Clara, additional, De Benedetti, Fabrizio, additional, and Martini, Alberto, additional

Published
2018
Full Text
View/download PDF

163. Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis

Author

ter Haar, Nienke M., primary, Tak, Tamar, additional, Mokry, Michal, additional, Scholman, Rianne C., additional, Meerding, Jenny M., additional, de Jager, Wilco, additional, Verwoerd, Anouk, additional, Foell, Dirk, additional, Vogl, Thomas, additional, Roth, Johannes, additional, Leliefeld, Pieter H. C., additional, van Loosdregt, Jorg, additional, Koenderman, Leo, additional, Vastert, Sebastiaan J., additional, and de Roock, Sytze, additional

Published
2018
Full Text
View/download PDF

164. Treating juvenile idiopathic arthritis to target: recommendations of an international task force

Author

Ravelli, Angelo, primary, Consolaro, Alessandro, additional, Horneff, Gerd, additional, Laxer, Ronald M, additional, Lovell, Daniel J, additional, Wulffraat, Nico M, additional, Akikusa, Jonathan D, additional, Al-Mayouf, Sulaiman M, additional, Antón, Jordi, additional, Avcin, Tadej, additional, Berard, Roberta A, additional, Beresford, Michael W, additional, Burgos-Vargas, Ruben, additional, Cimaz, Rolando, additional, De Benedetti, Fabrizio, additional, Demirkaya, Erkan, additional, Foell, Dirk, additional, Itoh, Yasuhiko, additional, Lahdenne, Pekka, additional, Morgan, Esi M, additional, Quartier, Pierre, additional, Ruperto, Nicolino, additional, Russo, Ricardo, additional, Saad-Magalhães, Claudia, additional, Sawhney, Sujata, additional, Scott, Christiaan, additional, Shenoi, Susan, additional, Swart, Joost F, additional, Uziel, Yosef, additional, Vastert, Sebastiaan J, additional, and Smolen, Josef S, additional

Published
2018
Full Text
View/download PDF

165. Patient’s experiences with the care for juvenile idiopathic arthritis across Europe

Author

van Dijkhuizen, E. H. Pieter., primary, Egert, Tsipi, additional, Egert, Yona, additional, Costello, Wendy, additional, Schoemaker, Casper, additional, Fernhout, Marlous, additional, Kepic, Mirjam, additional, Martini, Alberto, additional, Scala, Silvia, additional, Rotstein-Grein, Ingrid, additional, Vastert, Sebastiaan J., additional, and Wulffraat, Nico M., additional

Published
2018
Full Text
View/download PDF

167. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: The SHARE initiative

Author

Immuno/reuma onderzoek 1 (Vastert), Child Health, Medical Humanities Onderzoek Team 2, JC onderzoeksprogramma Methodologie, Cluster B, Reumatologie patientenzorg, Infection & Immunity, BOO, Divisieleiding O&O, Regenerative Medicine and Stem Cells, Immunologie/Reumatologie, Infectiezieken, Reumatologie onderzoek 2, Groot, Noortje, De Graeff, Nienke, Avcin, Tadej, Bader-Meunier, Brigitte, Dolezalova, Pavla, Feldman, Brian M., Kenet, Gili, Koné-Paut, Isabelle, Lahdenne, Pekka, Marks, Stephen D, McCann, Liza J., Pilkington, Clarissa A., Ravelli, Angelo, Van Royen-Kerkhof, Annet, Uziel, Yosef, Vastert, Sebastiaan J., Wulffraat, Nico M., Ozen, Seza, Brogan, Paul A., Kamphuis, Sylvia, Beresford, Michael W., Immuno/reuma onderzoek 1 (Vastert), Child Health, Medical Humanities Onderzoek Team 2, JC onderzoeksprogramma Methodologie, Cluster B, Reumatologie patientenzorg, Infection & Immunity, BOO, Divisieleiding O&O, Regenerative Medicine and Stem Cells, Immunologie/Reumatologie, Infectiezieken, Reumatologie onderzoek 2, Groot, Noortje, De Graeff, Nienke, Avcin, Tadej, Bader-Meunier, Brigitte, Dolezalova, Pavla, Feldman, Brian M., Kenet, Gili, Koné-Paut, Isabelle, Lahdenne, Pekka, Marks, Stephen D, McCann, Liza J., Pilkington, Clarissa A., Ravelli, Angelo, Van Royen-Kerkhof, Annet, Uziel, Yosef, Vastert, Sebastiaan J., Wulffraat, Nico M., Ozen, Seza, Brogan, Paul A., Kamphuis, Sylvia, and Beresford, Michael W.

Published
2017

168. Enhancers in autoimmune arthritis: Implications and therapeutic potential

Author

Infection & Immunity, CMM Groep Coffer, Child Health, Reumatologie patientenzorg, Immuno/reuma onderzoek 1 (Vastert), CTI Van Wijk, Immunologie onderzoek 2, Peeters, Janneke G. C., Vastert, Sebastiaan J, van Wijk, Femke, van Loosdregt, Jorg, Infection & Immunity, CMM Groep Coffer, Child Health, Reumatologie patientenzorg, Immuno/reuma onderzoek 1 (Vastert), CTI Van Wijk, Immunologie onderzoek 2, Peeters, Janneke G. C., Vastert, Sebastiaan J, van Wijk, Femke, and van Loosdregt, Jorg

Published
2017

169. Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative

Author

Kuemmerle-Deschner, Jasmin B, primary, Hansmann, Sandra, additional, Wulffraat, Nico M, additional, Vastert, Sebastiaan J, additional, Hens, Kristien, additional, Anton, Jordi, additional, Avcin, Tadej, additional, Martini, Alberto, additional, Koné-Paut, Isabelle, additional, Uziel, Yosef, additional, Ravelli, Angelo, additional, Wouters, Carine, additional, Shaw, David, additional, Özen, Seza, additional, Eikelberg, Andreas, additional, Prakken, Berent J, additional, Ruperto, Nicolino, additional, Horneff, Gerd, additional, Constantin, Tamas, additional, Beresford, Michael W, additional, Sikken, Marijn, additional, Foster, Helen E, additional, Haug, Iris, additional, Schuller, Sabrina, additional, Jägle, Christine, additional, and Benseler, Susanne M, additional

Published
2017
Full Text
View/download PDF

170. Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study.

Author

Dijkhuizen, E. H. Pieter, Del Chierico, Federica, Malattia, Clara, Russo, Alessandra, Pires Marafon, Denise, Haar, Nienke M., Magni‐Manzoni, Silvia, Vastert, Sebastiaan J., Dallapiccola, Bruno, Prakken, Berent, Martini, Alberto, Benedetti, Fabrizio, and Putignani, Lorenza

Subjects
FECAL analysis, AGE distribution, BIOMARKERS, CLOSTRIDIA, IMMUNITY, INFLAMMATION, LONGITUDINAL method, MEDICAL cooperation, SCIENTIFIC observation, POPULATION geography, RESEARCH, JUVENILE idiopathic arthritis, RNA, LOGISTIC regression analysis, GENOMICS, GUT microbiome, SYMPTOMS, DISEASE duration, STATISTICAL models
Abstract

Objective: To assess the composition of gut microbiota in Italian and Dutch patients with juvenile idiopathic arthritis (JIA) at baseline, with inactive disease, and with persistent activity compared to healthy controls. Methods: In a multicenter, prospective, observational cohort study, fecal samples were collected at baseline from 78 Italian and 21 Dutch treatment‐naive JIA patients with <6 months of disease duration and compared to 107 geographically matched samples from healthy children. Forty‐four follow‐up samples from patients with inactive disease and 25 follow‐up samples from patients with persistent activity were analyzed. Gut microbiota composition was determined by 16S ribosomal RNA–based metagenomics. Alpha‐ and β‐diversity were computed, and log ratios of relative abundance were compared between patients and healthy controls using random forest models and logistic regression. Results: Baseline samples from Italian patients showed reduced richness compared to healthy controls (P < 0.001). Random forest models distinguished between Italian patient baseline samples and healthy controls and suggested differences between Dutch patient samples and healthy controls (areas under the curve >0.99 and 0.71, respectively). The operational taxonomic units (OTUs) of Erysipelotrichaceae (increased in patients), Allobaculum (decreased in patients), and Faecalibacterium prausnitzii (increased in patients) showed different relative abundance in Italian patient baseline samples compared to controls after controlling for multiple comparisons. Some OTUs differed between Dutch patient samples and healthy controls, but no evidence remained after controlling for multiple comparisons. No differences were found in paired analysis between Italian patient baseline and inactive disease samples. Conclusion: Our findings show evidence for dysbiosis in JIA patients. Only patient/control status, age, and geographic origin appear to be drivers of the microbiota profiles, regardless of disease activity stage, inflammation, and markers of autoimmunity. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

171. The human microbiome and juvenile idiopathic arthritis

Author

Verwoerd, Anouk, ter Haar, Nienke M., de Roock, Sytze, Vastert, Sebastiaan J., Bogaert, Debby, Verwoerd, Anouk, ter Haar, Nienke M., de Roock, Sytze, Vastert, Sebastiaan J., and Bogaert, Debby

Published
2016

172. Autoimmune disease-associated gene expression is reduced by BET-inhibition

Author

Peeters, Janneke G C, Vervoort, Stephin J, Mijnheer, Gerdien, de Roock, Sytze, Vastert, Sebastiaan J, Nieuwenhuis, Edward E S, van Wijk, Femke, Prakken, Berent J, Mokry, Michal, van Loosdregt, Jorg, Peeters, Janneke G C, Vervoort, Stephin J, Mijnheer, Gerdien, de Roock, Sytze, Vastert, Sebastiaan J, Nieuwenhuis, Edward E S, van Wijk, Femke, Prakken, Berent J, Mokry, Michal, and van Loosdregt, Jorg

Published
2016

173. The human microbiome and juvenile idiopathic arthritis

Author

CTI Vastert, Infection & Immunity, Child Health, CTI Van Loosdregt, Reumatologie patientenzorg, Infectieziekten onderzoek3 (Bogaert), Verwoerd, Anouk, ter Haar, Nienke M., de Roock, Sytze, Vastert, Sebastiaan J., Bogaert, Debby, CTI Vastert, Infection & Immunity, Child Health, CTI Van Loosdregt, Reumatologie patientenzorg, Infectieziekten onderzoek3 (Bogaert), Verwoerd, Anouk, ter Haar, Nienke M., de Roock, Sytze, Vastert, Sebastiaan J., and Bogaert, Debby

Published
2016

174. Autoimmune disease-associated gene expression is reduced by BET-inhibition

Author

CMM Groep Coffer, CTI Van Wijk, Infection & Immunity, CTI Van Loosdregt, Child Health, Reumatologie patientenzorg, Zorg en O&O, Regenerative Medicine and Stem Cells, Immuno/reuma onderzoek 1 (Vastert), Circulatory Health, CTI Vastert, Reumatologie onderzoek 2, Divisieleiding O&O, MDL onderzoek 3, Immunologie onderzoek 2, Peeters, Janneke G C, Vervoort, Stephin J, Mijnheer, Gerdien, de Roock, Sytze, Vastert, Sebastiaan J, Nieuwenhuis, Edward E S, van Wijk, Femke, Prakken, Berent J, Mokry, Michal, van Loosdregt, Jorg, CMM Groep Coffer, CTI Van Wijk, Infection & Immunity, CTI Van Loosdregt, Child Health, Reumatologie patientenzorg, Zorg en O&O, Regenerative Medicine and Stem Cells, Immuno/reuma onderzoek 1 (Vastert), Circulatory Health, CTI Vastert, Reumatologie onderzoek 2, Divisieleiding O&O, MDL onderzoek 3, Immunologie onderzoek 2, Peeters, Janneke G C, Vervoort, Stephin J, Mijnheer, Gerdien, de Roock, Sytze, Vastert, Sebastiaan J, Nieuwenhuis, Edward E S, van Wijk, Femke, Prakken, Berent J, Mokry, Michal, and van Loosdregt, Jorg

Published
2016

176. Autoimmune disease-associated gene expression is reduced by BET-inhibition

Author

Peeters, Janneke G.C., primary, Vervoort, Stephin J., additional, Mijnheer, Gerdien, additional, de Roock, Sytze, additional, Vastert, Sebastiaan J., additional, Nieuwenhuis, Edward E.S., additional, van Wijk, Femke, additional, Prakken, Berent J., additional, Mokry, Michal, additional, and van Loosdregt, Jorg, additional

Published
2016
Full Text
View/download PDF

177. Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression

Author

Peeters, Janneke G C, Vervoort, Stephin J, Tan, Sander C, Mijnheer, Gerdien, de Roock, Sytze, Vastert, Sebastiaan J., Nieuwenhuis, Edward E S, van Wijk, Femke, Prakken, Berent J, Creyghton, Menno P, Coffer, Paul J, Mokry, Michal, van Loosdregt, Jorg, Peeters, Janneke G C, Vervoort, Stephin J, Tan, Sander C, Mijnheer, Gerdien, de Roock, Sytze, Vastert, Sebastiaan J., Nieuwenhuis, Edward E S, van Wijk, Femke, Prakken, Berent J, Creyghton, Menno P, Coffer, Paul J, Mokry, Michal, and van Loosdregt, Jorg

Published
2015

179. Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis

Author

Immuno/reuma onderzoek 1 (Vastert), Unit Opleiding Aios, Reumatologie patientenzorg, Infection & Immunity, Child Health, Reumatologie, Cluster B, Immuno/reuma patientenzorg, Circulatory Health, CTI Vastert, Bulatovic-Calasan, Maja, Vastert, Sebastiaan J., Scholman, Rianne C., Verweij, Frederik, Klein, Mark, Wulffraat, Nico W., Prakken, Berent J., van Wijk, Femke, Immuno/reuma onderzoek 1 (Vastert), Unit Opleiding Aios, Reumatologie patientenzorg, Infection & Immunity, Child Health, Reumatologie, Cluster B, Immuno/reuma patientenzorg, Circulatory Health, CTI Vastert, Bulatovic-Calasan, Maja, Vastert, Sebastiaan J., Scholman, Rianne C., Verweij, Frederik, Klein, Mark, Wulffraat, Nico W., Prakken, Berent J., and van Wijk, Femke

Published
2015

180. Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression

Author

CMM Groep Coffer, CTI Van Wijk, Infection & Immunity, CTI Van Loosdregt, Child Health, Immuno/reuma onderzoek 1 (Vastert), Reumatologie patientenzorg, Zorg en O&O, Regenerative Medicine and Stem Cells, Circulatory Health, CTI Vastert, Reumatologie onderzoek 2, Hubrecht Institute with UMC, Immunologie onderzoek 2, Cancer, MDL onderzoek 3, Peeters, Janneke G C, Vervoort, Stephin J, Tan, Sander C, Mijnheer, Gerdien, de Roock, Sytze, Vastert, Sebastiaan J., Nieuwenhuis, Edward E S, van Wijk, Femke, Prakken, Berent J, Creyghton, Menno P, Coffer, Paul J, Mokry, Michal, van Loosdregt, Jorg, CMM Groep Coffer, CTI Van Wijk, Infection & Immunity, CTI Van Loosdregt, Child Health, Immuno/reuma onderzoek 1 (Vastert), Reumatologie patientenzorg, Zorg en O&O, Regenerative Medicine and Stem Cells, Circulatory Health, CTI Vastert, Reumatologie onderzoek 2, Hubrecht Institute with UMC, Immunologie onderzoek 2, Cancer, MDL onderzoek 3, Peeters, Janneke G C, Vervoort, Stephin J, Tan, Sander C, Mijnheer, Gerdien, de Roock, Sytze, Vastert, Sebastiaan J., Nieuwenhuis, Edward E S, van Wijk, Femke, Prakken, Berent J, Creyghton, Menno P, Coffer, Paul J, Mokry, Michal, and van Loosdregt, Jorg

Published
2015

181. Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study.

Author

Dijkhuizen, Evert H Pieter van, Aidonopoulos, Orfeas, Haar, Nienke M ter, Marafon, Denise Pires, Magni-Manzoni, Silvia, Ioannidis, Yannis E, Putignani, Lorenza, Vastert, Sebastiaan J, Malattia, Clara, and Benedetti, Fabrizio De

Subjects
COMORBIDITY, ALGORITHMS, CYTOKINES, HEMOGLOBINS, INFLAMMATORY mediators, JOINTS (Anatomy), LONGITUDINAL method, MEDICAL cooperation, SCIENTIFIC observation, RESEARCH, RESEARCH evaluation, JUVENILE idiopathic arthritis, RISK assessment, GUT microbiome, SYMPTOMS, DISEASE duration, DISEASE complications
Abstract

Objectives To predict the occurrence of inactive disease in JIA in the first 2 years of disease. Methods An inception cohort of 152 treatment-naïve JIA patients with disease duration <6 months was analysed. Potential predictors were baseline clinical variables, joint US, gut microbiota composition and a panel of inflammation-related compounds in blood plasma. Various algorithms were employed to predict inactive disease according to Wallace criteria at 6-month intervals in the first 2 years. Performance of the models was evaluated using the split-cohort technique. The cohort was analysed in its entirety, and separate models were developed for oligoarticular patients, polyarticular RF negative patients and ANA positive patients. Results All models analysing the cohort as a whole showed poor performance in test data [area under the curve (AUC): <0.65]. The subgroup models performed better. Inactive disease was predicted by lower baseline juvenile arthritis DAS (JADAS)-71 and lower relative abundance of the operational taxonomic unit Mogibacteriaceae for oligoarticular patients (AUC in test data: 0.69); shorter duration of morning stiffness, higher haemoglobin and lower CXCL-9 levels at baseline for polyarticular RF negative patients (AUC in test data: 0.69); and shorter duration of morning stiffness and higher baseline haemoglobin for ANA positive patients (AUC in test data: 0.72). Conclusion Inactive disease could not be predicted with satisfactory accuracy in the whole cohort, likely due to disease heterogeneity. Interesting predictors were found in more homogeneous subgroups. These need to be validated in future studies. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

182. Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression

Author

Peeters, Janneke G.C., primary, Vervoort, Stephin J., additional, Tan, Sander C., additional, Mijnheer, Gerdien, additional, de Roock, Sytze, additional, Vastert, Sebastiaan J., additional, Nieuwenhuis, Edward E.S., additional, van Wijk, Femke, additional, Prakken, Berent J., additional, Creyghton, Menno P., additional, Coffer, Paul J., additional, Mokry, Michal, additional, and van Loosdregt, Jorg, additional

Published
2015
Full Text
View/download PDF

183. Recommendations for the management of autoinflammatory diseases

Author

ter Haar, Nienke M, primary, Oswald, Marlen, additional, Jeyaratnam, Jerold, additional, Anton, Jordi, additional, Barron, Karyl S, additional, Brogan, Paul A, additional, Cantarini, Luca, additional, Galeotti, Caroline, additional, Grateau, Gilles, additional, Hentgen, Veronique, additional, Hofer, Michael, additional, Kallinich, Tilmann, additional, Kone-Paut, Isabelle, additional, Lachmann, Helen J, additional, Ozdogan, Huri, additional, Ozen, Seza, additional, Russo, Ricardo, additional, Simon, Anna, additional, Uziel, Yosef, additional, Wouters, Carine, additional, Feldman, Brian M, additional, Vastert, Sebastiaan J, additional, Wulffraat, Nico M, additional, Benseler, Susanne M, additional, Frenkel, Joost, additional, Gattorno, Marco, additional, and Kuemmerle-Deschner, Jasmin B, additional

Published
2015
Full Text
View/download PDF

185. It is about time: the first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis.

Author

Pardeo, Manuela, Vastert, Sebastiaan J, and Benedetti, Fabrizio De

Subjects
*BIOMARKERS, *SERIAL publications, *JUVENILE idiopathic arthritis
Abstract

The author reflects on the approved biomarkers for the early diagnosis of systemic juvenile idiopathic arthritis (sJIA), which is a rare childhood polygenic autoinflammatory disease. Other topics include the sJIA symptoms like arthralgia, fever and rashes, the study which assessed the performance of myeloid-related protein 8/14 (MRP8/14) as diagnostic biomarker of sJIA, and the effectiveness of the interleukin 1 (IL-1) and IL-6 inhibitors in managing patients with sJIA.

Published
2022
Full Text
View/download PDF

186. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative.

Author

Groot, Noortje, de Graeff, Nienke, Avcin, Tadej, Bader-Meunier, Brigitte, Dolezalova, Pavla, Feldman, Brian, Kenet, Gili, Koné-Paut, Isabelle, Lahdenne, Pekka, Marks, Stephen D., McCann, Liza, Pilkington, Clarissa A., Ravelli, Angelo, van Royen-Kerkhof, Annet, Uziel, Yosef, Vastert, Sebastiaan J., Wulffraat, Nico M., Ozen, Seza, Brogan, Paul, and Kamphuis, Sylvia

Subjects
ANTIPHOSPHOLIPID syndrome, SYSTEMATIC reviews, EVIDENCE-based medicine, DIAGNOSIS
Abstract

Antiphospholipid syndrome (APS) is rare in children, and evidence-based guidelines are sparse. Consequently, management is mostly based on observational studies and physician's experience, and treatment regimens differ widely. The Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative was launched to develop diagnostic and management regimens for children and young adults with rheumatic diseases. Here, we developed evidence-based recommendations for diagnosis and treatment of paediatric APS. Evidence-based recommendations were developed using the European League Against Rheumatism standard operating procedure. Following a detailed systematic review of the literature, a committee of paediatric rheumatologists and representation of paediatric haematology with expertise in paediatric APS developed recommendations. The literature review yielded 1473 articles, of which 15 were valid and relevant. In total, four recommendations for diagnosis and eight for treatment of paediatric APS (including paediatric Catastrophic Antiphospholipid Syndrome) were accepted. Additionally, two recommendations for children born to mothers with APS were accepted. It was agreed that new classification criteria for paediatric APS are necessary, and APS in association with childhood-onset systemic lupus erythematosus should be identified by performing antiphospholipid antibody screening. Treatment recommendations included prevention of thrombotic events, and treatment recommendations for venous and/or arterial thrombotic events. Notably, due to the paucity of studies on paediatric APS, level of evidence and strength of the recommendations is relatively low. The SHARE initiative provides international, evidence-based recommendations for diagnosis and treatment for paediatric APS, facilitating improvement and uniformity of care. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

192. Development of Inflammatory Bowel Disease in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

Author

van DIJKEN, TRUDY D., primary, VASTERT, SEBASTIAAN J., additional, GERLONI, VALERIA M., additional, PONTIKAKI, IRENE, additional, LINNEMANN, KRISTINA, additional, GIRSCHICK, HERMANN, additional, ARMBRUST, WINEKE, additional, MINDEN, KIRSTEN, additional, PRINCE, FEMKE H.M., additional, KOKKE, FREDDY T.M., additional, NIEUWENHUIS, EDWARD E.S., additional, HORNEFF, GERD, additional, and WULFFRAAT, NICO M., additional

Published
2011
Full Text
View/download PDF

195. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis

Author

Vastert, Sebastiaan J., primary, van Wijk, Richard, additional, D’Urbano, Leila E., additional, de Vooght, Karen M. K., additional, de Jager, Wilco, additional, Ravelli, Angelo, additional, Magni-Manzoni, Silvia, additional, Insalaco, Antonella, additional, Cortis, Elisabetta, additional, van Solinge, Wouter W., additional, Prakken, Berent J., additional, Wulffraat, Nico M., additional, de Benedetti, Fabrizio, additional, and Kuis, Wietse, additional

Published
2009
Full Text
View/download PDF

197. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients.

Author

Bulatović Ćalasan, Maja, den Boer, Ethan, de Rotte, Maurits C. F. J., Vastert, Sebastiaan J., Kamphuis, Sylvia, de Jonge, Robert, and Wulffraat, Nico M.

Abstract

Objective To determine association of erythrocyte methotrexate polyglutamates (MTX-PG) with disease activity and adverse effects in a prospective juvenile idiopathic arthritis (JIA) cohort. Methods One hundred and thirteen JIA patients were followed from MTX start until 12 months. Erythrocyte MTX-PGs with 1-5 glutamate residues were measured at 3 months with tandem mass spectrometry. The outcomes were Juvenile Arthritis Disease Activity Score (JADAS)-27 and adverse effects. To determine associations of MTX-PGs with JADAS-27 at 3 months and during 1 year of MTX treatment, linear regression and linear mixed-model analyses were used. To determine associations of MTX-PGs with adverse effects during 1 year of MTX treatment, logistic regression was used. Analyses were corrected for JADAS-27 at baseline and co-medication. Results Median JADAS-27 decreased from 12.7 (IQR: 7.8-18.2) at baseline to 2.9 (IQR: 0.1-6.5) at 12 months. Higher concentrations of MTX-PG3 (β: -0.006, p=0.005), MTX-PG4 (β: -0.015, p=0.004), MTX-PG5 (β: -0.051, p=0.011) and MTX-PG3-5 (β: -0.004, p=0.003) were associated with lower disease activity at 3 months. Higher concentrations of MTX-PG3 (β: -0.005, p=0.028), MTX-PG4 (β: -0.014, p=0.014), MTX-PG5 (β: -0.049, p=0.023) and MTX-PG3-5 (β: -0.004, p=0.018) were associated with lower disease activity over 1 year. None of the MTX-PGs was associated with adverse effects. Conclusions In the first prospective study in JIA, long-chain MTX-PGs were associated with lower JADAS-27 at 3 months and during 1 year of MTX treatment. Erythrocyte MTX-PG could be a plausible candidate for therapeutic drug monitoring of MTX in JIA. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

198. Validation of Relapse Risk Biomarkers for Routine Use in Patients With Juvenile Idiopathic Arthritis.

Author

Rothmund, Friederike, Gerss, Joachim, Ruperto, Nicolino, Däbritz, Jan, Wittkowski, Helmut, Frosch, Michael, Wulffraat, Nico M., Wedderburn, Lucy R., Holzinger, Dirk, Gohar, Faekah, Vastert, Sebastiaan J., Brik, Riva, Job Deslandre, Chantal, Melo-Gomes, Jose Antonio, Saad Magalhães, Claudia, Barcellona, Roberto, Russo, Ricardo, Gattorno, Marco, Martini, Alberto, and Roth, Johannes

Published
2014
Full Text
View/download PDF

199. FOXP3.

Author

Schadenberg, Alvin W. L., Vastert, Sebastiaan J., Evens, Fabiola C. M., Kuis, Wietse, van Vught, Adrianus J., Jansen, Nicolaas J. G., and Prakken, Berent J.

Published
2011
Full Text
View/download PDF

200. Validation of the EQ-5D-Y-5L parent-proxy version among children with juvenile idiopathic arthritis.

Author

Ohinmaa, Arto, Wen, Jiabi, Currie, Gillian R., Benseler, Susanne M, Swart, Joost F, Vastert, Sebastiaan J, Yeung, Rae S M, and Marshall, Deborah A.

Subjects
*JUVENILE idiopathic arthritis, *JOINT pain, *QUALITY of life, *PSYCHOMETRICS, *ONE-way analysis of variance
Abstract

Objectives: Juvenile idiopathic arthritis (JIA) is the most common type of arthritis among children. It can cause joint pain and permanent physical damage, which affects mobility and daily activities. The EQ-5D-Y-3L self-report version has been validated in JIA, but the validity of EQ-5D-Y-5L remains unknown. We examined the psychometric properties of the EQ-5D-Y-5L parent-proxy version among children with JIA. Methods: We used data from the Understanding Childhood Arthritis Network Canadian-Dutch collaboration study cohort, including patients with new-onset JIA, and those starting or stopping biologics. Clinical data and the parent-proxy version of the childhood health assessment questionnaire (CHAQ) and EQ-5D-Y-5L were collected. We evaluated the ceiling and floor effect; convergent and divergent validity using Spearman's rank correlation; known-group validity using one-way ANOVA (Analysis of Variance) and effect size; and informativity using Shannon's evenness index. Results: 467 patient visits representing 407 patients were analyzed. The EQ-5D-Y-5L had no ceiling/floor effect. The EQ-5D-Y-5L showed good convergent (e.g., EQ-5D-Y-5L pain/discomfort dimension vs. CHAQ pain index (Spearman's r = 0.74, 95% confidence interval (C.I.): 0.69–0.79)), divergent (e.g., EQ-5D-Y-5L pain/discomfort dimension vs. CHAQ eating dimension (Spearman's r = 0.19, 95% C.I.: 0.09–0.29)) and known-group validity (e.g., mean EQ-5D-Y-5L level summary score for patients with inactive versus active disease status, 6.34 vs. 10.52 (p < 0.001, effect size = 1.20 (95% C.I.: 0.95–1.45)). Shannon's evenness index ranged from 0.52 to 0.88, suggesting most dimensions had relatively even distributions. Conclusions: In this patient sample, EQ-5D-Y-5L parent-proxy version exhibited construct validity and informativity, suggesting the EQ-5D-Y-5L can be used to measure the quality of life of children with JIA. Plain English summary: Juvenile idiopathic arthritis is the most common type of arthritis affecting children. It can cause pain and permanent physical damage to joints and affects mobility and daily activities. While there is no cure yet, new therapies like biologics are effective. However, biologics are expensive and can have side effects. To decide when is the best time to use these biologics, we need to understand their cost and impact on patients. EQ-5D-Y-5L is a common tool to measure how the disease affects a patient's life. It is unclear whether EQ-5D-Y-5L works well for patients with juvenile idiopathic arthritis. In this study, we compared the EQ-5D-Y-5L to another tool that measures how the illness impacts functional ability. We looked to see if the EQ-5D-Y-5L could tell the difference between children who were more or less sick. We also assessed whether the EQ-5D-Y-5L has the ability to describe patients with different severity in health status. This study indicates that the EQ-5D-Y-5L is a good tool to measure the health of patients with juvenile idiopathic arthritis. Findings from this study support the use of the EQ-5D-Y-5L among this patient population in future clinical trials and research studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results